Clinical Perspectives Presented by:

Five-Year Outcomes With First-Line Nivolumab + Ipilimumab With Chemotherapy vs Chemotherapy in Patients With Metastatic NSCLC in CheckMate 9LA Please see US Full Prescribing Information for OPDIVO. Please see US Full Prescribing Information for OPDIVO. Thoracic Oncologist, Clinical Professor in Oncology at Stanford University, CA Chief, Department of Oncology in Palo Medical Oncologist, Cancer Care University of Central Florida, FL Thoracic Oncologist, Clinical Professor in Oncology at Stanford University,

Read the full article here

Source: www.ajmc.com

Categories: General Journals & Societ, General Medicine News

Tags: NSCLC,ClinicalPerspectives

Tweets with this article

AJMC

What are the clinical implications of 5-year CheckMate 9LA results in metastatic #NSCLC? Experts discuss long-term impact of nivolumab + ipilimumab + chemo vs chemo alone, key insights, and evolving treatment strategies. Get the #ClinicalPerspectives: https://t.co/cNmMhp8XDY

Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM

Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated…

NEJM June 16, 2025

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, Highlights Key Reasons to Attend OPC 2025

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and…

Pharmacy Times June 16, 2025

Cancer before 40: Mayo Clinic expert shares 3 topics that younger patients often want to discuss – Mayo Clinic News Network

Mayo Clinic physician Dr. Rosenthal shares three topics that younger people with cancer often want to discuss with their healthcare teams.

Mayo Clinic June 16, 2025

Related Articles